# Concert Pharmaceuticals clinical trials: 33 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials with Concert Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Concert Pharmaceuticals: 33 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/concert-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 28, 2022 | NCT05478772 | Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects | Concert Pharmaceuticals | Phase 1 | Completed | Health Volunteers | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05478772) |
| July 21, 2022 | NCT05468749 | Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543 | Concert Pharmaceuticals | Phase 1 | Completed | Renal Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05468749) |
| July 20, 2022 | NCT05467722 | Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543 | Concert Pharmaceuticals | Phase 1 | Completed | Hepatic Impairment | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05467722) |
| July 20, 2022 | NCT05467709 | Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects | Concert Pharmaceuticals | Phase 1 | Completed | Health Volunteers | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05467709) |
| July 20, 2022 | NCT05467696 | Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers | Concert Pharmaceuticals | Phase 1 | Completed | Health Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05467696) |
| January 14, 2022 | NCT05192369 | A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers | Concert Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05192369) |
| April 13, 2021 | NCT04843540 | Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects | Concert Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04843540) |
| March 15, 2021 | NCT04797650 | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) | Concert Pharmaceuticals | Phase 3 | Completed | Alopecia Areata | 517 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04797650) |
| March 5, 2021 | NCT04784533 | A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | Concert Pharmaceuticals | Phase 2 | Completed | Alopecia Areata | 317 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04784533) |
| February 8, 2021 | NCT04743414 | Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects | Concert Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04743414) |
| August 19, 2020 | NCT04518995 | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) | Concert Pharmaceuticals | Phase 3 | Completed | Alopecia Areata | 706 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04518995) |
| March 16, 2020 | NCT04309643 | Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects | Concert Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04309643) |
| November 12, 2019 | NCT04158687 | A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia | Concert Pharmaceuticals | Phase 2 | Completed | Schizophrenia | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04158687) |
| September 17, 2019 | NCT04092712 | Study Evaluating Pharmacokinetics and Mass Balance of \[14C\]-CTP-543 in Healthy Adult Male Volunteers | Concert Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04092712) |
| May 8, 2019 | NCT03941548 | Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata | Concert Pharmaceuticals | Phase 2 | Completed | Alopecia Areata | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03941548) |
| March 19, 2019 | NCT03880253 | Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers | Concert Pharmaceuticals | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03880253) |
| March 19, 2019 | NCT03880136 | Food Effect Study of CTP-543 in Healthy Volunteers | Concert Pharmaceuticals | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03880136) |
| February 5, 2019 | NCT03830463 | Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers | Concert Pharmaceuticals | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03830463) |
| January 22, 2019 | NCT03811912 | Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata | Concert Pharmaceuticals | Phase 2 | Completed | Alopecia Areata | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03811912) |
| December 19, 2018 | NCT03778320 | A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers | Concert Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03778320) |
| May 2, 2017 | NCT03137381 | Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata | Concert Pharmaceuticals | Phase 2 | Completed | Alopecia Areata | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03137381) |
| November 10, 2016 | NCT02960945 | Open-Label Crossover Study Comparing CTP-543 to Jakafi® | Concert Pharmaceuticals | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02960945) |
| May 19, 2016 | NCT02777008 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects | Concert Pharmaceuticals | Phase 1 | Completed | Healthy | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02777008) |
| February 11, 2016 | NCT02680249 | Food Effect Study of CTP-656 in Healthy Male Volunteers | Concert Pharmaceuticals | Phase 1 | Completed | Healthy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02680249) |
| November 9, 2015 | NCT02599792 | Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656 | Concert Pharmaceuticals | Phase 1 | Completed | Healthy | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02599792) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 25 |
| Phase 2 | 6 |
| Phase 3 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 33 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Alopecia Areata | 6 |
| Alopecia | 2 |
| Hair Diseases | 2 |
| Renal Insufficiency, Chronic | 2 |
| Schizophrenia | 1 |
| Narcolepsy | 1 |
| Disorders of Excessive Somnolence | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Diabetic Nephropathies | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Persian restaurants in the United States](https://specstream.ai/data/businesses/persian-restaurants/united-states)
- [Textile manufacturers in the United States](https://specstream.ai/data/businesses/textile-manufacturers/united-states)
- [B2B radio and television commercials companies in the United States](https://specstream.ai/data/businesses/b2b-radio-and-television-commercials-companies/united-states)
- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
- [Ice suppliers in the United States](https://specstream.ai/data/businesses/ice-suppliers/united-states)
